• 1
    Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987; 55: 6166.
  • 2
    Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80( Suppl): 15881594.
  • 3
    Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88: 10821090.
  • 4
    Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol. 1991; 18( Suppl 5): 1115.
  • 5
    Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL. Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol. 1996; 57: 370376.
  • 6
    Mariette X, Khalifa P, Ravaud P, et al. Bone densitometry in patients with multiple myeloma. Am J Med. 1992; 93: 595598.
  • 7
    Dodwell DJ, Howell A. The systemic treatment of bone metastases. In: RubensRD, FogelmanI, eds. Bone metastases: diagnosis and treatment. London: Springer-Verlag, 1991: 121148.
  • 8
    Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996; 334: 488493.
  • 9
    Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998; 16: 593602.
  • 10
    Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335: 17851791.
  • 11
    Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16: 20382044.
  • 12
    Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996; 73: 10891095.
  • 13
    Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998; 339: 398400.
  • 14
    Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998; 339: 357363.
  • 15
    Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000; 18: 13781391.
  • 16
    Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens RD, Fogelman I. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med. 1988; 29: 13541359.
  • 17
    Frank J, Ling A, Patronas N, Carrasquillo J, Horvath K, Dwyer A. Comparison of magnetic resonance imaging and radionuclide bone scan in the evaluation of primary and metastatic disease to the bone [abstract 25]. Proc Am Soc Clin Oncol. 1989; 8: 7.
  • 18
    Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999; 17: 23812389.
  • 19
    Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev. 1996; 22: 289331.
  • 20
    Coleman RE. Assessment of response to treatment. In: RubensRD, FogelmanI, eds. Bone metastases: diagnosis and treatment. London: Springer-Verlag, 1991: 103111.
  • 21
    Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman I, Rubens RD. Biochemical prediction of response of bone metastases to treatment. Br J Cancer. 1988; 58: 205210.
  • 22
    Woitge HW, Pecherstorfer M, Li Y, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999; 14: 792801.
  • 23
    Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998; 34: 20212026.
  • 24
    Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol. 1999; 11: 312319.
  • 25
    Vinholes JJF, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double- blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997; 8: 12431250.
  • 26
    Miura H, Yamamoto I, Takada M, et al. Diagnostic validity of bone metabolic markers for bone metastasis. Endocr J. 1997; 44: 751757.
  • 27
    Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986; 319: 516518.
  • 28
    Delaisse JM, Eeckhout Y, Neff L, et al. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. J Cell Sci. 1993; 106: 10711082.
  • 29
    Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem. 1996; 271: 1251112516.
  • 30
    Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996; 271: 1251712524.
  • 31
    Peacock M, Robertson WG, Nordin BE. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969; 1: 384386.
  • 32
    Campbell FC, Blamey RW, Woolfson AM, Elston CW, Hosking DJ. Calcium excretion (CaE) in metastatic breast cancer. Br J Surg. 1983; 70: 202204.
  • 33
    Pecherstorfer M, Zimmer-Roth I, Schilling T, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995; 80: 97103.
  • 34
    Deacon AC, Hulme P, Hesp R, Green JR, Tellez M, Reeve J. Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin Chim Acta. 1987; 166: 297306.
  • 35
    Gasser A, Celada A, Courvoisier B, et al. The clinical measurement of urinary total hydroxyproline excretion. Clin Chim Acta. 1979; 95: 487491.
  • 36
    Mautalen CA. Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J Lab Clin Med. 1970; 75: 1118.
  • 37
    Gasser AB, Depierre D, Courvoisier B. Total urinary and free serum hydroxyproline in metastatic bone disease. Br J Cancer. 1979; 39: 280283.
  • 38
    Blomqvist C, Elomaa I, Virkkunen P, et al. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer. 1987; 60: 29072912.
  • 39
    Body JJ, Dumon JC, Piccart M, Ford J. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res. 1995; 10: 11911196.
  • 40
    Coombes RC, Dady P, Parsons C, et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 1983; 52: 610614.
  • 41
    Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. 1994; 74: 29492955.
  • 42
    O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol. 1995; 13: 929934.
  • 43
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994; 40: 20222025.
  • 44
    Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 1992; 7: 12511258.
  • 45
    Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab. 1992; 3: 263270.
  • 46
    Walls J, Assiri A, Howell A, et al. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer. 1999; 80: 12651270.
  • 47
    Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res. 1994; 9: 16431649.
  • 48
    Eastell R, Hampton L, Colwell A, et al. Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption [abstract]. Osteoporosis. 1990; 2: 469470.
  • 49
    Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 1991; 6: 639644.
  • 50
    Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem. 1995; 41: 14891494.
  • 51
    Body JJ, Dumon JC, Delmas PD. Comparative evaluation of markers of bone resorption after a single dose of pamidronate in patients with breast cancer induced osteolysis. Bone Miner. 1994; 25( Suppl 1): S77.
  • 52
    Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992; 65: 766768.
  • 53
    Bonde M, Qvist P, Fledelius P, Garnero P, Christiansen C. Effect of bisphosphonate therapies (pamidronate and ibandronate) on the excretion of degradation products of the C-telopeptides of type I collagen measured by a radioimmunoassay (Crosslaps™ RIA) [abstract 45]. Bone. 1995; 17: 609.
  • 54
    Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer. 1997; 75: 408412.
  • 55
    Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. J Clin Oncol. 1997; 15: 131138.
  • 56
    Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer. 1999; 80: 221228.
  • 57
    Yamamoto I, Morita R, Fujimoto R, et al. Clinical studies using measurements of N-telopeptides of type I collagen (NTx) in patients with bone metastases. Comparison with bone scintigraphy and other metabolic markers. Kaku Igaku. 1995; 32: 501510.
  • 58
    Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem. 1997; 30: 573593.
  • 59
    Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999; 45: 13591368.
  • 60
    Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 1994; 54: 28232826.
  • 61
    Withold W, Armbruster FP, Karmatschek M, Reinauer H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin Chem. 1997; 43: 8591.
  • 62
    Bellahcene A, Albert V, Pollina L, Basolo F, Fisher LW, Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid. 1998; 8: 637641.
  • 63
    Bellahcene A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res. 1996; 11: 665670.
  • 64
    Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer. 1996; 69: 350353.
  • 65
    Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R, Armbruster FP. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem. 1997; 43: 20762082.
  • 66
    Waltregny D, Bellahcene A, Van Riet I,et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst. 1998; 90: 10001008.
  • 67
    Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000; 11: 7682.
  • 68
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000; 82: 858864.
  • 69
    Koizumi M, Yonese J, Fukui I, Ogata E. The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int. 2001; 87: 348351.
  • 70
    Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab. 2001; 19: 4551.
  • 71
    Akimoto S, Furuya Y, Akakura K, Ito H. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J. 1998; 45: 97104.
  • 72
    Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995; 71: 10611064.
  • 73
    Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev. 2001; 27: 187192.
  • 74
    Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998; 22: 403408.
  • 75
    Berenson JR, Vescio R, Rosen L, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001; 7: 478485.
  • 76
    Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001; 91: 144154.
  • 77
    Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91: 11911200.